Outcomes and Risk Factors Associated With Failures of Debridement, Antibiotics, and Implant Retention in Patients With Acute Hematogenous Periprosthetic Joint Infection
- PMID: 33620172
- DOI: 10.5435/JAAOS-D-20-00939
Outcomes and Risk Factors Associated With Failures of Debridement, Antibiotics, and Implant Retention in Patients With Acute Hematogenous Periprosthetic Joint Infection
Abstract
Background: Acute hematogenous periprosthetic joint infections (PJI) accounts for 20% to 35% of all PJI cases. Treatment options include débridement, antibiotics, and implant retention (DAIR) or implant revision (single-stage/two-stage revision). Because the reported success rates of DAIR for acute PJIs as reported in the literature varies widely, this study aimed to investigate (1) the outcome of DAIR as revision surgery procedure and (2) the potential risk factors for treatment failure of DAIR in patients with acute hematogenous PJI.
Methods: We reviewed 106 consecutive cases of total joint arthroplasty patients who underwent DAIR for the diagnosis of acute hematogenous PJI. Outcomes of the cohort including infection free survival was investigated. Mean follow-up was 4.9 years. Demographics, case data, comorbidities, and extremity score were analyzed by univariate and multivariate regressions to identify risk factors for failure of DAIR.
Results: The failure rate of patients who underwent DAIR was 23.6% (25 of 106 patients). Univariate regression demonstrated that diabetes mellitus (P = 0.01) and polymicrobial infections (P < 0.01) are associated with failure of DAIR. Multivariate regression confirmed diabetes mellitus and polymicrobial infections as independent risk factors for failure of DAIR.
Discussion: Debridement, antibiotics, and implant retention may be a viable treatment option with moderate failure rates at the midterm follow-up in cases of acute hematogenous PJI. The study also identified diabetes mellitus and polymicrobial infections as independent risk factors for failure of DAIR. The findings of this study provide clinically useful information for surgeons in treatment of patients with acute hematogenous PJI.
Copyright © 2021 by the American Academy of Orthopaedic Surgeons.
References
-
- Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J: Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res 2010;468:52-56.
-
- Klemt C, Tirumala V, Smith EJ, Padmanabha A, Kwon YM: Development of a preoperative risk calculator for re-infection following revision surgery for periprosthetic joint infection. J Arthroplasty 2021;36:693-699.
-
- Urish KL, Bullock AG, Kreger AM, et al.: A multicenter study of irrigation and debridement in total knee arthroplasty periprosthetic joint infection: Treatment failure is high. J Arthroplasty 2018;33:1154-1159.
-
- Klemt C, Smith EJ, Tirumala V, Bounajem G, van den Kieboom J, Kwon YM: Outcomes and risk factors associated with 2-stage reimplantation requiring an interim spacer exchange for periprosthetic joint infection. J Arthroplasty 2020; September 14 [Epub ahead of print].
-
- Fink B, Schuster P, Schwenninger C, Frommelt L, Oremek D: A standardized regimen for the treatment of acute postoperative infections and acute hematogenous infections associated with hip and knee arthroplasties. J Arthroplasty 2017;32:1255-1261.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
